Valeant Files Quarterly Report, Avoiding Default on Debt

Valeant Pharmaceuticals International Inc. filed its first-quarter report with U.S. regulators on Tuesday, avoiding a default on its debt and beating a self-imposed deadline.

The drugmaker had failed to file the report for months, and creditors sent the company notices of default.

Before it's here, it's on the Bloomberg Terminal.